CS99 I am in full agreement:

"In my opinion, the reduction in CHF readmissions is the most promising result in BETonMACE when it comes getting approval. The fact it was a secondary endpoint is not such a big deal. It was statistically significant and was in the total sample, not a subgroup."

Because (to reinforce) the power of the study is based on the entire BOM study population and not in a smaller sub-group of the whole study population. Don needs to take advantage of the BTD here to fast track ABL and get it out to market as this has to be the cheapest and quickest route in that regard.

IMO ... Koo